Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1Carcinoma, Small Cell 1

Interventions

Magnetic Resonance Spectroscopy 15lutetium Lu 177 dotatate 14Specimen Handling 14cabozantinib 10Nivolumab 10Everolimus 8pembrolizumab 7gallium Ga 68 dotatate 6Ipilimumab 6Cisplatin 5Carboplatin 5trametinib 4olaparib 4lenvatinib 4X-Rays 4Lutetium-177 4Etoposide 4Cyclophosphamide 4CTLA-4 Antigen 4fluorodopa F 18 3fludarabine 3dabrafenib 3cemiplimab 3Temozolomide 3Phantoms, Imaging 3Fluorodeoxyglucose F18 3Blood Specimen Collection 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3selpercatinib 2lanreotide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
PT-100 dipeptide × Endocrine × 90 days × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡